Outlier in a BE study [Outliers]

posted by Dr_Dan  – Germany, 2013-11-14 15:41 (3869 d 01:14 ago) – Posting: # 11887
Views: 10,232

Dear Auditor
According to CPMP/QWP/EWP/1401/98 Rev. 1 unbiased assessment of results from randomised studies requires that all subjects are observed and treated according to the same rules. These rules should be independent from treatment or outcome. In consequence, the decision to exclude a subject from the statistical analysis must be specified in the protocol and made before bioanalysis. Exclusion of data cannot be accepted on the basis of statistical analysis or for pharmacokinetic reasons alone, because it is impossible to distinguish the formulation effects from other effects influencing the pharmacokinetics. Bad luck :-(
However, you can try to present both study results (with and without outlier) to the authorities but in this case you need a reasonable explanation why the subject under discussion is an oulier (cave: Exclusion of data cannot be accepted on the basis of statistical analysis or for pharmacokinetic reasons!). You need to find evidence in the subject´s medical history, behaviour, state of health etc. which allows to assume that this subject behaves different.
If the subject shows a different profile for the reference product you might have a chance. If you want to exclude the subject due to a different profile under test, no way! :no:
Hope this helps
Kind regards
Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,057 posts in 4,840 threads, 1,641 registered users;
39 visitors (0 registered, 39 guests [including 9 identified bots]).
Forum time: 17:56 CEST (Europe/Vienna)

You should treat as many patients as possible with the new drugs
while they still have the power to heal.    Armand Trousseau

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5